Research

LeadDesks Q4 var blandet. Rentabiliteten oversteg klart vores forventninger, men ARR-udviklingen var svag.

Pressemeddelelsen uddybede ikke baggrunden for opsigelsen, men vi anser det for sandsynligt, at Duells svage præstation har ført til opsigelsen af den administrerende direktør.

Faron is preparing for an important financing round.

I år fokuserer selskabet på at fortsætte med at forbedre resultaterne udover integrationen af Sarastia.

Today, we publish our updated North Media A/S investment case following the FY 2025 annual report and earnings call. North Media delivered operational stabilization in 2025, with EBIT recovering to DKK 66 mio. and free cash flow turning strongly positive at DKK 69 mio., while guiding for further improvement in 2026. The stock continues to trade at a significant discount to peers, driven to a significant extent by the large securities portfolio.

Eezy har meddelt, at de planlægger en større fortegningsemission for at styrke deres finansielle position.

Following last year's weak performance, the company's growth story has taken a clear hit, which is also reflected in the share price.

Efter årsregnskabet for 2025 i sidste uge fra Føroya Banki, og efter at de fleste banker i peer group har aflagt årsregnskab har vi opdateret vores one-pager på banken.

In connection with the annual report, we have updated our Investment Case One-pager for Curasight. 2025 marked a defining transition for the company — from building and validating its uPAR platform to actively advancing its therapeutic program uTREAT into the clinic. The highlight of the year was the dosing of the first patient in the Phase 1 glioblastoma trial in December, marking the initiation of Curasight's first-ever clinical trial under its therapeutic platform. Combined with a strengthened capital base and continued progress on the diagnostic platform uTRACE, the company enters 2026 as an active clinical-stage radioligand therapy developer with two significant data readouts on the horizon.

We expect Q4’25 revenue and adjusted EBIT, excluding large non-recurring items, to have improved, which would seal the significant turnaround in earnings achieved in the past financial year.

We see significant growth opportunities for Talenom, especially in Spain, but for now, the company generates its profit and cash flow in Finland.

The earnings improvement promised in Q3 appears to have materialized.

We initiate coverage of Easor with an Accumulate recommendation and a target price of EUR 1.0.

Sunborn Internationals H2-tal var svagere end vores forventninger på grund af en overraskende blød belægningsgrad pr. værelse.

Forventningerne til indeværende år er klart positive, men vi har sænket vores estimater.

Vi anser udsigterne for de kommende år for især de voksende forretningsområder for at være opmuntrende.

EcoUps regnskabsmeddelelse var samlet set en smule mere afdæmpet end vores allerede lave forventninger.

Lamors Q4-resultater var lidt svagere end vores forventninger, men guidancen stemte overens med vores estimater.

Guidance var bedre end vores forventninger og baner vejen for igangsættelse af projekter.